Diffuse White Matter Damage Is Absent in Neuromyelitis Optica

References

1. 1.↵
   1. Wingerchuk DM,
   2. Lennon VA,
   3. Lucchinetti CF,
   4. et al

   . The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–15

   CrossRefPubMedWeb of Science
2. 2.↵
   1. de Seze J,
   2. Lebrun C,
   3. Stojkovic T,
   4. et al

   . Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003; 9: 521–25

   Abstract/FREE Full Text
3. 3.↵
   1. Weinshenker BG,
   2. Wingerchuk DM,
   3. Nakashima I,
   4. et al

   . OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006; 5: 110–11

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Wingerchuk DM,
   2. Lennon VA,
   3. Pittock SJ,
   4. et al

   . Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–89

   Abstract/FREE Full Text
5. 5.↵
   1. Lennon VA,
   2. Wingerchuk DM,
   3. Kryzer TJ,
   4. et al

   . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106–12

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Lucchinetti CF,
   2. Mandler RN,
   3. McGavern D,
   4. et al

   . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450–61

   Abstract/FREE Full Text
7. 7.↵
   1. Sinclair C,
   2. Kirk J,
   3. Herron B,
   4. et al

   . Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 2007; 113: 187–94

   CrossRefPubMed
8. 8.↵
   1. Roemer SF,
   2. Parisi JE,
   3. Lennon VA,
   4. et al

   . Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194–205

   Abstract/FREE Full Text
9. 9.↵
   1. Warabi Y,
   2. Matsumoto Y,
   3. Hayashi H

   . Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007; 252: 57–61 Epub 2006 Nov 27

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Wingerchuk DM,
    2. Pittock SJ,
    3. Lucchinetti CF,
    4. et al

    . A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68: 603–5

    Abstract/FREE Full Text
11. 11.↵
    1. Miller DH,
    2. Weinshenker BG,
    3. Filippi M,
    4. et al

    . Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157–74

    Abstract/FREE Full Text
12. 12.↵
    1. Sarchielli P,
    2. Presciutti O,
    3. Pelliccioli GP,
    4. et al

    . Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999; 122: 513–21

    Abstract/FREE Full Text
13. 13.↵
    1. Wattjes MP,
    2. Harzheim M,
    3. Kuhl CK,
    4. et al

    . Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 2006; 27: 1794–98

    Abstract/FREE Full Text
14. 14.↵
    1. Bagory M,
    2. Durand-Dubief F,
    3. Ibarrola D,
    4. et al

    . “Absolute” quantification in magnetic resonance spectroscopy: validation of a clinical protocol in multiple sclerosis. Conf Proc IEEE Eng Med Biol Soc 2007; 1: 3458–61
15. 15.↵
    1. Rigotti DJ,
    2. Inglese M,
    3. Gonen O

    . Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007; 28: 1843–49

    Abstract/FREE Full Text
16. 16.↵
    1. Bitsch A,
    2. Bruhn H,
    3. Vougioukas V,
    4. et al

    . Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999; 20: 1619–27

    Abstract/FREE Full Text
17. 17.↵
    1. Jansen JF,
    2. Backes WH,
    3. Nicolay K,
    4. et al

    . 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006; 240: 318–32

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Jarius S,
    2. Aboul-Enein F,
    3. Waters P,
    4. et al

    . Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131 (Pt 11): 3072–80 Epub 2008 Oct 22

    Abstract/FREE Full Text
19. 19.↵
    1. Krampla W,
    2. Aboul-Enein F,
    3. Jecel J,
    4. et al

    . Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 2009; 19: 2535–43 Epub 2009 May 5

    CrossRefPubMed
20. 20.↵
    1. Naressi A,
    2. Couturier C,
    3. Castang I,
    4. et al

    . Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001; 31: 269–86

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Naressi A,
    2. Couturier C,
    3. Devos JM,
    4. et al

    . Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 2: 141–52
22. 22.↵
    1. de Beer R,
    2. van den Boogaart A,
    3. van Ormondt D,
    4. et al

    . Application of time-domain fitting in the quantification of in vivo 1H spectroscopic imaging data sets. NMR Biomed 1992; 5: 171–78

    PubMedWeb of Science
23. 23.↵
    1. Vanhamme L,
    2. van den Boogaart A,
    3. Van Huffel S

    . Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129: 35–43

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Wansapura JP,
    2. Holland SK,
    3. Dunn RS,
    4. et al

    . NMR relaxation times in the human brain at 3.0 Tesla. J Magn Reson Imaging 1999; 9: 531–38

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Mlynárik V,
    2. Gruber S,
    3. Moser E,
    4. et al

    . Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed 2001; 14: 325–31

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Bichuetti DB,
    2. Rivero RL,
    3. de Oliveira EM,
    4. et al

    . White matter spectroscopy in neuromyelitis optica: a case control study. J Neurol 2008; 255: 1895–99

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Wattjes MP,
    2. Harzheim M,
    3. Lutterbey GG,
    4. et al

    . Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007; 28: 1517–22

    Abstract/FREE Full Text
28. 28.↵
    1. B Benedetti B,
    2. Rovaris M,
    3. Rocca MA,
    4. et al

    . In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 2009; 15: 789–94

    Abstract/FREE Full Text